Nichole Tanner to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Nichole Tanner has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
2.627
-
Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease. Am J Respir Crit Care Med. 2017 09 01; 196(5):602-608.
Score: 0.449
-
POINT: Is N2 Disease a Contraindication for Surgical Resection for Superior Sulcus Tumors? Yes. Chest. 2015 Dec; 148(6):1373-1375.
Score: 0.398
-
Rebuttal From Drs Tanner and Silvestri. Chest. 2015 Dec; 148(6):1379-1380.
Score: 0.398
-
Convex probe endobronchial ultrasound. Semin Respir Crit Care Med. 2014 Dec; 35(6):636-44.
Score: 0.372
-
Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. J Thorac Oncol. 2012 Feb; 7(2):365-9.
Score: 0.305
-
The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer. 2012 May; 76(2):131-7.
Score: 0.302
-
Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. Chest. 2020 07; 158(1):406-415.
Score: 0.135
-
Invasive Mediastinal Staging in Lung Cancer. Use a Prediction Model or Just Do It? Am J Respir Crit Care Med. 2017 06 15; 195(12):1556-1558.
Score: 0.111
-
Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Chest. 2014 Aug; 146(2):406-411.
Score: 0.091
-
Lung cancer: progress in diagnosis, staging and therapy. Respirology. 2010 Jan; 15(1):44-50.
Score: 0.066